Mebendazole Market Emerging Trends and Future Growth Projections during 2020-2025 | Changzhou Yabang-QH, Aarambh, Adani Pharmachem, Shanghai Ziqi, Xi'an Janssen, Cadila Pharmaceuticals

The exclusive research report on Global Mebendazole market 2020 categorizes the market based on market overview, regions, analysis by types and applications, market dynamics, manufacturers profiles and forecast 2020-2025.

Global Mebendazole Market overview:

Mebendazole (MBZ) is a medication used to treat a number of parasitic worm infestations. This includes ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others. It is taken by mouth. Mebendazole is usually well tolerated. The Global Mebendazole Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/275730 .

On the Basis of Product Type segment, the Mebendazole Market is sub segmented into greater than 98% and greater than 99% and Other. Based on End Use Industry segment, the Mebendazole Market is segmented as Feed Additives, Tablet and Oral Suspension.

There are several manufacturers of Mebendazole in Europe and North America. In North America, the demand for Mebendazole is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Mebendazole Market Report 2020” @ https://www.businessindustryreports.com/buy-now/275730/single .

Top Industry News:

Cadila Pharmaceuticals launches Obetocad, a generic Obeticholic Acid (Ocaliva) in the liver therapy on 08 September, 2020 -- Cadila Pharmaceuticals is amongst the first brands to launch generic Obeticholic Acid (Ocaliva), in India. The molecule is used to treat Primary Biliary Cholangitis (PBC).

Ahmedabad: Cadila Pharmaceuticals launches Obetocad in India, a generic version of Ocaliva (Obeticholic Acid) primarily used for the treatment of Primary Biliary Cholangitis (PBC).

For the treatment of PBC, currently Ursodeoxycholic acid (UDCA) is being extensively used. Around 40% of the patients do not respond to UDCA treatment and 5-10% of patients observe severe side effects. Obetocad can be used as a monotherapy or along with UDCA for treatment of patients who are unresponsive to UDCA therapy.

“There is an unmet need in the treatment of PBC. Ursodeoxycholic Acid is the only approved standard of care but a major chunk of the patients do not respond to the treatment. Obetocad containing Obetocholic Acid is now DCGI approved and shows positive results in patients. This generic drug is launched for the first time in the country, and with Obetocad, we hope to provide an option to all the patients of PBC” shared Mr. Narendra Deode, Vice President, Cadila Pharmaceuticals.

“With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. With Obetocad, we plan to provide a quality solution to the patients of PBC who do not get relief from other standard therapy options. We are constantly working towards finding the next innovative drug for our patients” said Mr. O.P. Singh, President -Sales and Marketing, Cadila Pharmaceuticals Limited.

Obetocad is available in 5 mg and 10 mg tablets in packs of 10 tablets. It is also USFDA and EMA approved and recently received its DCGI approvals. Obetocad also has the potential to be used in other indications such as NASH, NAFLD, severe acute hepatitis, bile acid diarrhoea, bariatric and gallstone diseases.

Cadila Pharmaceuticals has always been focused on making sure high quality, affordable and life-saving treatments are within the reach of patients. Recently, Sepsivac an innovative drug from Cadila Pharma received the pharma excellence award for being the most promising drug in the fight against COVID-19. Cadila Pharma has also recently launched 4 biosimilar products in the past 2 months under the brand name Bevaro, Ritucad, Cadalimab and NuPTH for treatment of cancer and osteoporosis. Cadila plans to launch multiple biosimilar products this year for the Indian Market.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/275730 .

Major Key Players:

Some of the Mebendazole Market manufacturers involved in the market are Changzhou Yabang-QH Pharmachem, Aarambh Life Science, Neha Pharma Private Limited, Adani Pharmachem Private Limited, Shanghai Ziqi Biotechnology, Xi'an Janssen Pharmaceutical, Shaanxi Hanjiang Pharmaceutical Group, Hubei Widely Chemical Technology; Cadila Pharmaceuticals in World, effective mergers are some of the strategies adopted by the Mebendazole Market manufacturers. New product launches and continuous technological innovations are the Mebendazole Market strategies adopted by the major players.

Table of Contents:

1 Mebendazole Product Definition
2 Global Mebendazole Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Mebendazole Shipments
2.2 Global Manufacturer Mebendazole Business Revenue
2.3 Global Mebendazole Market Overview
3 Manufacturer Mebendazole Business Introduction
3.1 Changzhou Yabang-QH Pharmachem Mebendazole Business Introduction
3.1.1 Changzhou Yabang-QH Pharmachem Mebendazole Shipments, P≥99%, Revenue and Gross profit 2020-2025
3.1.2 Changzhou Yabang-QH Pharmachem Mebendazole Business Distribution by Region
3.1.3 Changzhou Yabang-QH Pharmachem Interview Record
3.1.4 Changzhou Yabang-QH Pharmachem Mebendazole Business Profile
3.1.5 Changzhou Yabang-QH Pharmachem Mebendazole Product Specification
3.2 Aarambh Life Science Mebendazole Business Introduction
3.2.1 Aarambh Life Science Mebendazole Shipments, P≥99%, Revenue and Gross profit 2020-2025
3.2.2 Aarambh Life Science Mebendazole Business Distribution by Region
3.2.3 Interview Record
3.2.4 Aarambh Life Science Mebendazole Business Overview
3.2.5 Aarambh Life Science Mebendazole Product Specification
3.3 NEHA PHARMA PRIVATE LIMITED Mebendazole Business Introduction
3.3.1 NEHA PHARMA PRIVATE LIMITED Mebendazole Shipments, P≥99%, Revenue and Gross profit 2020-2025
3.3.2 NEHA PHARMA PRIVATE LIMITED Mebendazole Business Distribution by Region
3.3.3 Interview Record
3.3.4 NEHA PHARMA PRIVATE LIMITED Mebendazole Business Overview
3.3.5 NEHA PHARMA PRIVATE LIMITED Mebendazole Product Specification
3.4 Adani Pharmachem Private Limited Mebendazole Business Introduction
3.5 Shanghai Ziqi Biotechnology Mebendazole Business Introduction
3.6 Xi’an Janssen Oral Suspension Mebendazole Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.